title: [Clinical Summarization of Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: A Report of 100 Cases].
abstract: OBJECTIVE
  To analyze the treatment outcome of a consecutive series of 100 leukemia patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  The clinical data of leukemia patients received allo-HSCT were analyzed retrospectively, the therapeutic efficacy was summarized. 100 evaluable cases of leukemia included 47 cases of AML, 33 cases of ALL, 2 cases of AL (biphenotypic), 16 CML and 2 CMML. Before transplantation, 76 cases were in first complete remission, 9 cases in second or greater complete remission and 15 cases in non-remission or relapse. All the patients received peripheral blood hematopoietic stem cell transplantation (PBHSCT). The conditioning regimen of human leukocyte antigen (HLA)-matched allo-HSCT group was modified BuCy, but in HLA-mismatched group Fludarabine and anti-human thymocyte globulin (ATG) was added. CsA+MTX regimen was used for prophylaxis of graft-versus-host disease (GVHD) in HLA-identical allo-HSCT, while additional MMF was added in HLA-mismatched group. The average time of follow-up was 13 months.
  
  
  RESULTS
  At the last follow-up, 66.0% (66/100) patients survived, 53.0% (53/100) patients survived without leukemia, 28.0% (28/100) patients relapsed and 34.0% (34/100) patients died, 44.1% patients of them died from infectious pulmonary complications. During transplantation, 65.0% of the patients were suffered from lung infection. The overall survival (OS) and disease-free survival (DFS) of all cases was 60.9% and 48.8%, respectively. The recurrence rate was significantly higher in non-remission (66.7%) than in CR (21.2%) patients (P < 0.05). The cumulative incidence of GVHD in HLA-mismatched transplantation was 60.8%, which was significantly higher than that of HLA-matched transplantation (38.8%) (P < 0.05).
  
  
  CONCLUSIONS
  Allo-HSCT can cure a significant proportion of leukemia patients, especially for those in CR status. Since the incidence of infectious pulmonary complications after allo-HSCT is still high, much more attention should be paid to it. The comprehensive prognosis of HLA-matched transplantation is better than the HLA-mis-matched transplantation.
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: Qing-Xin
authors.initials: QX
authors.lastname: Huang
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: San-Fang
authors.initials: SF
authors.lastname: Tu
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Huang
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: Yu-Xian
authors.initials: YX
authors.lastname: Huang
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: Lan
authors.initials: L
authors.lastname: Deng
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: Bing-Yi
authors.initials: BY
authors.lastname: Wu
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China.
authors.forename: Chao-Yang
authors.initials: CY
authors.lastname: Song
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, Guangdong Province, China. E-mail: liyuhua2011gz@163.com.
authors.forename: Yu-Hua
authors.initials: YH
authors.lastname: Li
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D015994:Incidence; D007938:Leukemia / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000961:Antilymphocyte Serum; D006680:HLA Antigens; D014740:Vidarabine; C024352:fludarabine